PolyPid (PYPD) Other Non-Current Liabilities (2019 - 2026)
PolyPid (PYPD) posted Other Non-Current Liabilities of $401000.0 for Q1 2026, little changed sequentially from $400000.0 in Q4 2025, and down 0.74% YoY from $404000.0 in Q1 2025.
PolyPid (PYPD) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
PolyPid has reported Other Non-Current Liabilities for 8 years, with the latest figure at $401000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 0.74% year-over-year to $401000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $401000.0 (down 0.74% YoY) and the FY2025 annual result came in at $400000.0, up 1.01% from the prior year.
- Other Non-Current Liabilities held at $401000.0 in Q1 2026 per PYPD's latest filing, from $400000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $476000.0 in Q3 2025 and troughed at $84000.0 in Q2 2022.
- A 5-year average of $355235.3 and a median of $400000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities slumped 55.79% in 2022, then soared 430.95% in 2023.
- Over 5 years, Other Non-Current Liabilities stood at $294000.0 in 2022, then soared by 35.37% to $398000.0 in 2023, then slipped by 0.5% to $396000.0 in 2024, then grew by 1.01% to $400000.0 in 2025, then rose by 0.25% to $401000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $401000.0, $400000.0, and $476000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PolyPid | 113.86 Mn | 107.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 413,000.00 |
| Mar 31, 2026 | 401,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 476,000.00 |
| Jun 30, 2025 | 454,000.00 |
| Mar 31, 2025 | 404,000.00 |
| Dec 31, 2024 | 396,000.00 |
| Sep 30, 2024 | 461,000.00 |
| Jun 30, 2024 | 371,000.00 |
| Mar 31, 2024 | 403,000.00 |
| Dec 31, 2023 | 398,000.00 |
| Sep 30, 2023 | 451,000.00 |
| Jun 30, 2023 | 446,000.00 |
| Mar 31, 2023 | 314,000.00 |
| Dec 31, 2022 | 294,000.00 |
| Sep 30, 2022 | 91,000.00 |
| Jun 30, 2022 | 84,000.00 |
| Mar 31, 2022 | 195,000.00 |
| Dec 31, 2021 | 199,000.00 |
| Sep 30, 2021 | 192,000.00 |